These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 30110697)

  • 1. Long-Term Outcomes of Full-Fluence and Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
    Son BK; Kim K; Kim ES; Yu SY
    Ophthalmologica; 2019; 241(2):105-115. PubMed ID: 30110697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
    Matušková V; Vysloužilová D; Uher M
    Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing effects of photodynamic therapy in central serous chorioretinopathy: full-dose versus half-dose versus half-dose-half-fluence.
    Park W; Kim M; Kim RY; Park YH
    Graefes Arch Clin Exp Ophthalmol; 2019 Oct; 257(10):2155-2161. PubMed ID: 31367848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Cheng CK; Chang CK; Peng CH
    Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal fluence rate of photodynamic therapy for chronic central serous chorioretinopathy.
    Park DG; Jeong S; Noh D; Sagong M
    Br J Ophthalmol; 2021 Jun; 105(6):844-849. PubMed ID: 32727733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy.
    Nicoló M; Eandi CM; Alovisi C; Grignolo FM; Traverso CE; Musetti D; Cardillo Piccolino F
    Am J Ophthalmol; 2014 May; 157(5):1033-7. PubMed ID: 24487046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser.
    van Rijssen TJ; van Dijk EHC; Scholz P; Breukink MB; Dijkman G; Peters PJH; Tsonaka R; Keunen JEE; MacLaren RE; Hoyng CB; Downes SM; Fauser S; Boon CJF
    Acta Ophthalmol; 2021 Nov; 99(7):805-811. PubMed ID: 33565230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.
    Sheptulin V; Purtskhvanidze K; Roider J
    Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2027-2034. PubMed ID: 30097783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
    Smretschnig E; Ansari-Shahrezaei S; Hagen S; Glittenberg C; Krebs I; Binder S
    Retina; 2013 Feb; 33(2):316-23. PubMed ID: 23314238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multimodal retinal imaging in central serous chorioretinopathy treated with oral eplerenone or photodynamic therapy.
    Rabiolo A; Zucchiatti I; Marchese A; Baldin G; Sacconi R; Montorio D; Cicinelli MV; Querques L; Bandello F; Querques G;
    Eye (Lond); 2018 Jan; 32(1):55-66. PubMed ID: 29265111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CHOROIDAL THICKNESS AFTER FULL-FLUENCE AND HALF-FLUENCE PHOTODYNAMIC THERAPY IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Oh BL; Yu HG
    Retina; 2015 Aug; 35(8):1555-60. PubMed ID: 25932547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular and structural alterations of the choroid evaluated by optical coherence tomography angiography and optical coherence tomography after half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
    Demirel S; Özcan G; Yanık Ö; Batıoğlu F; Özmert E
    Graefes Arch Clin Exp Ophthalmol; 2019 May; 257(5):905-912. PubMed ID: 30617579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical research on one-third dose verteporfin photodynamic therapy in the treatment of chronic central serous chorioretinopathy.
    Hua L; Lin B; Hong J; Min HB; Han WL; Zhou TY; Zhang ZQ
    Eur Rev Med Pharmacol Sci; 2018 Jan; 22(2):278-284. PubMed ID: 29424884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of reduced-fluence photodynamic therapy for central serous chorioretinopathy associated with combined serous retinal detachment and fovea-involving pigment epithelial detachment.
    Arf S; Hocaoglu M; Sayman Muslubas I; Karacorlu M
    Int Ophthalmol; 2017 Jun; 37(3):483-489. PubMed ID: 27392913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optical Coherence Tomography Angiography Findings in Chronic Central Serous Chorioretinopathy After Photodynamic Therapy.
    Tang PH; Shields R; Silva RA
    Ophthalmic Surg Lasers Imaging Retina; 2019 Jan; 50(1):25-32. PubMed ID: 30640392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Retinochoroidal Vascular and Structural Changes after Half-Dose Photodynamic Therapy versus Half-Fluence Photodynamic Therapy Based on Optical Coherence Tomography Angiography in Eyes with Chronic Central Serous Chorioretinopathy.
    Karasu B; Akbas YB; Aykut A; Celebi ARC
    Ophthalmologica; 2022; 245(4):323-334. PubMed ID: 35249031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy.
    van Rijssen TJ; van Dijk EHC; Dijkman G; Boon CJF
    Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1395-1402. PubMed ID: 29732468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PHOTODYNAMIC THERAPY FOR SYMPTOMATIC SUBFOVEAL RETINAL PIGMENT EPITHELIAL DETACHMENT IN CENTRAL SEROUS CHORIORETINOPATHY: Outcomes and Prognostic Factors.
    Hwang S; Kang SW; Kim SJ; Jang JW; Kim KT
    Retina; 2019 Jun; 39(6):1117-1124. PubMed ID: 29517581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COMPARISON OF SHORT-TERM EFFICACY BETWEEN ORAL SPIRONOLACTONE TREATMENT AND PHOTODYNAMIC THERAPY FOR THE TREATMENT OF NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY.
    Lee JH; Lee SC; Kim H; Lee CS
    Retina; 2019 Jan; 39(1):127-133. PubMed ID: 29095358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial.
    Bae SH; Heo J; Kim C; Kim TW; Shin JY; Lee JY; Song SJ; Park TK; Moon SW; Chung H
    Ophthalmology; 2014 Feb; 121(2):558-65. PubMed ID: 24268858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.